gemcitabine has been researched along with ceritinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghanem, NB; Jamshed, MB; Li, X; Muhammad, SA; Munir, F; Sadiq, U; Shahid, N; Zhang, Q; Zhong, H | 1 |
| Adjei, A; Attwood, K; Bshara, W; Evans, R; Fountzilas, C; Ghasemi, M; Goey, A; Groman, A; Iyer, R; Ma, WW; Opyrchal, M; Wilton, J | 1 |
1 trial(s) available for gemcitabine and ceritinib
| Article | Year |
|---|---|
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfones | 2021 |
1 other study(ies) available for gemcitabine and ceritinib
| Article | Year |
|---|---|
Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Size; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfones; Xenograft Model Antitumor Assays | 2020 |